Reuters logo
10 months ago
BRIEF-Neurocrine says INGREZZA NDA for treatment of tardive dyskinesia has been accepted for priority review by U.S. FDA
October 11, 2016 / 11:21 AM / 10 months ago

BRIEF-Neurocrine says INGREZZA NDA for treatment of tardive dyskinesia has been accepted for priority review by U.S. FDA

1 Min Read

Oct 11 (Reuters) - Neurocrine Biosciences Inc :

* Neurocrine announces INGREZZA (valbenazine) new drug application for the treatment of tardive dyskinesia has been accepted for priority review by U.S. FDA

* Neurocrine Biosciences Inc- INGREZZA application has been given a prescription drug user fee act (PDUFA) target action date of April 11, 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below